Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data
2023 · Liver International · 110 citations
https://doi.org/10.1111/liv.15641
A
Andrea Casadei‐Gardini
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
376
Papers
7.2K
Citations
45
h-index
172
i10-index
Andrea Casadei‐Gardini is an academic researcher from University of Modena and Reggio Emilia. The author has contributed to research in topics: Hepatocellular Carcinoma Treatment and Prognosis & Cholangiocarcinoma and Gallbladder Cancer Studies & Liver Disease Diagnosis and Treatment. The author has an h-index of 45, co-authored 320 publications.
ORCID: 0000-0001-6289-7202Papers by this author
worksImmune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
2016 · Oncotarget · 94 citations
https://doi.org/10.18632/oncotarget.11565
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
2021 · JHEP Reports · 65 citations
https://doi.org/10.1016/j.jhepr.2021.100260
Clustered protocadherins methylation alterations in cancer
2019 · Clinical Epigenetics · 60 citations
https://doi.org/10.1186/s13148-019-0695-0
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
2017 · Scientific Reports · 36 citations
https://doi.org/10.1038/srep42499
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer
2018 · Radiation Oncology · 33 citations
https://doi.org/10.1186/s13014-018-1035-9
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat